Skip to main content

Advertisement

SpringerLink
Log in

Identification of a novel fusion gene, RARA::ANKRD34C, in acute promyelocytic leukemia

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

A Correction to this article was published on 27 March 2024

This article has been updated

Abstract

Acute promyelocytic leukemia (APL) is a specific subtype of acute myeloid leukemia that is distinguished by the chromosomal translocation t(15;17)(q24;q21), which leads to the fusion of the promyelocytic leukemia (PML) gene with the retinoic acid receptor alpha (RARA). Recently, we identified a novel fusion gene in APL, RARA::ankyrin repeat domain 34C (ANKRD34C), identified its functions by morphological, cytogenetic, molecular biological and multiplex fluorescence in situ hybridization analyses, and demonstrated the potential therapeutic effect clinically and experimentally of all-trans retinoic acid (ATRA); the findings have important implications for the diagnosis and treatment of atypical APL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data availability

The data of this study are available from the corresponding author upon reasonable request.

Change history

References

  1. Wang ZY, Chen Z (2008) Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 111(5):2505–2515

    Article  CAS  PubMed  Google Scholar 

  2. Dos Santos GA, Kats L, Pandolfi PP (2013) Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia. J Exp Med 210(13):2793–2802

    Article  PubMed  PubMed Central  Google Scholar 

  3. Yilmaz M, Kantarjian H, Ravandi F (2021) Acute promyelocytic leukemia current treatment algorithms. Blood Cancer J 11(6):123

    Article  PubMed  PubMed Central  Google Scholar 

  4. Kayser S, Schlenk RF, Platzbecker U (2018) Management of patients with acute promyelocytic leukemia. Leukemia 32(6):1277–1294

    Article  PubMed  Google Scholar 

  5. Wen L, Xu Y, Yao L et al (2019) Clinical and molecular features of acute promyelocytic leukemia with variant retinoid acid receptor fusions. Haematologica 104(5):e195–e199

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Yan W, Zhang G (2016) Molecular characteristics and clinical significance of 12 fusion genes in acute promyelocytic leukemia: a systematic review. Acta Haematol 136(1):1–15

    Article  CAS  PubMed  Google Scholar 

  7. Hussain L, Maimaitiyiming Y, Islam K et al (2019) Acute promyelocytic leukemia and variant fusion proteins: PLZF-RARα fusion protein at a glance. Semin Oncol 46(2):133–144

    Article  CAS  PubMed  Google Scholar 

  8. Chinese Society of Hematology, Chinese Medical Doctor Association; Chinese Medical Association, Chinese Medical Doctor Association. Chinese guidelines for diagnosis and treatment of acute promyelocytic leukemia (2018). Zhonghua Xue Ye Xue Za Zhi. 2018;39(3):179–183

  9. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391–405

    Article  CAS  PubMed  Google Scholar 

  10. Jimenez JJ, Chale RS, Abad AC et al (2020) Acute promyelocytic leukemia (APL): a review of the literature. Oncotarget 11(11):992–1003

    Article  PubMed  PubMed Central  Google Scholar 

  11. Vitaliano-Prunier A, Halftermeyer J, Ablain J et al (2014) Clearance of PML/RARA-bound promoters suffice to initiate APL differentiation. Blood 124(25):3772–3780

    Article  CAS  PubMed  Google Scholar 

  12. Chambon P (2005) The nuclear receptor superfamily: a personal retrospect on the first two decades. Mol Endocrinol 19(6):1418–1428

    Article  CAS  PubMed  Google Scholar 

  13. Wang Z, Wen L, Zhang L, Xu X, Chen X, Yao L, Wang M, Shen Z, Mo G, Wang Y, Zhao D, Cai W, Shen J, Chi X, Xu Y, Zeng Z, Pan J, Ruan C, Wu D, Jia Z, Chen S (2021) Identification of a novel TNRC18-RARA fusion in acute promyelocytic leukemia lacking t(15;17)(q24;q12)/PML-RARA. Mol Carcinog 60(2)

  14. Sakamoto H, Ando K, Imaizumi Y et al (2022) Alvocidib inhibits IRF4 expression via super-enhancer suppression and adult T-cell leukemia/lymphoma cell growth. Cancer Sci 113(12):4092–4103

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Dong S, Tweardy DJ (2002) Interactions of STAT5b-RARalpha, a novel acute promyelocytic leukemia fusion protein, with retinoic acid receptor and STAT3 signaling pathways. Blood 99(8):2637–2646

    Article  CAS  PubMed  Google Scholar 

  16. Dong S, Chen SJ, Tweardy DJ (2003) Cross-talk between retinoic acid and STAT3 signaling pathways in acute promyelocytic leukemia. Leuk Lymphoma 44(12):2023–2029

    Article  CAS  PubMed  Google Scholar 

  17. Albanesi J, Noguera NI, Banella C et al (2020) Transcriptional and metabolic dissection of ATRA-induced granulocytic differentiation in NB4 acute promyelocytic leukemia cells. Cells 9(11):2423

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Lachowiez C, DiNardo CD, Konopleva M (2020) Venetoclax in acute myeloid leukemia - current and future directions. Leuk Lymphoma 61(6):1313–1322

    Article  CAS  PubMed  Google Scholar 

  19. Tewari D, Patni P, Bishayee A et al (2022) Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: a novel therapeutic strategy. Semin Cancer Biol 80:1–17

    Article  PubMed  Google Scholar 

  20. Liu W, Yu WM, Zhang J et al (2017) Inhibition of the Gab2/PI3K/mTOR signaling ameliorates myeloid malignancy caused by Ptpn11 (Shp2) gain-of-function mutations. Leukemia 31(6):1415–1422

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported by the Nanjing Municipal Health Commission under the Nanjing Medical Science and Technology Development Key Project (YKK22087).

Author information

Author notes

  1. Yue Chen and Mengge Pan contributed equally to this article.

Authors and Affiliations

  1. Department of Hematology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210008, China

    Mengge Pan, Lanxin Chen, Miaoxin Peng, Zhenyu Liu, Ying Du, Yonggong Yang & Peipei Xu

  2. Nanjing Drum Tower Hospital Clinical College of Jiangsu University, Nanjing, 210008, China

    Yue Chen

  3. Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, 210008, China

    Yiran Fang

Authors
  1. Yue Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mengge Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lanxin Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Miaoxin Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zhenyu Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yiran Fang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ying Du
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yonggong Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Peipei Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Ying Du, Yonggong Yang, Lanxin Chen, Miaoxin Peng, and Peipei Xu conceived and designed the study. Yue Chen, Mengge Pan, Yiran Fang, and Zhenyu Liu analyzed the experimental data. Yue Chen, Mengge Pan, and Zhenyu Liu drafted the manuscript. All authors approved the final version of the manuscript.

Corresponding authors

Correspondence to Yonggong Yang or Peipei Xu.

Ethics declarations

Ethics approval

All participating sites received Institutional Review Board or ethics committees’ approval for the protocol. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008(5).

Informed consent

Informed consent was obtained from all individual participants included in the study.

Conflict of interest

The authors report there are no competing interests to declare.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original version of this article was revised: This article was originally published without Yonggong Yang presented as co-corresponding author.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chen, Y., Pan, M., Chen, L. et al. Identification of a novel fusion gene, RARA::ANKRD34C, in acute promyelocytic leukemia. Ann Hematol 103, 1181–1185 (2024). https://doi.org/10.1007/s00277-024-05629-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-024-05629-8

Keywords

Search

Navigation